Opvia
Accelerate bioprocesses with AI
Opvia reduce the time taken to develop bio-processes by 10X, while increasing product quality and enabling reduced production costs. They achieve this by offering a platform which combines non-invasive in situ data acquisition with proprietary models and ML. Advanced therapeutics such as cell and gene therapies will provide cures to currently incurable diseases, and synthetic biology will revolutionise industrial manufacturing, energy and food production.
However, the cost of production is preventing these technologies from reaching scale. Opvia are positioned to enable the biotech revolution.
Founder
Will Moss
CEO, Opvia
Data scientist and Chemical Engineering and Biotechnology graduate